| | Webinar: Accelerating NASH Clinical Trials Tuesday, June 15 | 10am ET / 7am PT Join industry leaders for a webinar dedicated to overcoming key challenges presented in NASH drug development. We’ll explore key considerations for liver biopsy collection and interpretation, emerging non-invasive biomarkers, and the connection between clinical practice and drug development. Register now. |
Sanofi, GSK kick-start phase 3 COVID-19 vax test as the pair targets variants, Q4 approval Eli Lilly's COVID-19 antibody halted in 6 more states as Regeneron's competing option sails along GlaxoSmithKline, Vir snag FDA authorization for new COVID-19 antibody. But how will they sell it without a supply deal? UPDATED Coronavirus tracker: CVS offering sweepstakes to drive more people to get vaccinated Eli Lilly hit with DOJ subpoena over New Jersey factory making COVID-19 drug Novartis, Molecular Partners kick off global trial for COVID-19 drug with phase 2 data expected this summer A DNA COVID-19 vaccine, delivered with help of electrical pulse, shows early promise Pandemic relief: Pharma sales rep salaries—and job satisfaction—actually increased in 2020 COVID-19 tracker: U.S. intel can't yet determine source of virus; Sanofi, GSK launch phase 3 vaccine trial Children's Hospital Colorado sounds alarm on 'unsustainable' spike in pediatric mental health cases Featured Story | By Ben Adams Just two weeks after seeing a positive data readout from a small midstage test, Sanofi and GlaxoSmithKline got the signoff for a much bigger phase 3, which could lead to a full approval by the fourth quarter. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy The U.S. has halted the distribution of Lilly’s COVID-19 antibody combination of bamlanivimab and etesevimab in Arizona, California, Florida, Indiana, Oregon and Washington—all states where coronavirus variants from Brazil and South Africa account for more than 10% of those with the disease. The FDA recommends providers in these states use Regeneron's antibody cocktail. read more By Angus Liu Following in the footsteps of Eli Lilly and Regeneron, a partnership between GlaxoSmithKline and Vir Biotechnology won an emergency FDA nod for a COVID-19 antibody drug. The difference? It doesn’t have a supply deal with the U.S. government. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn Eli Lilly said in an SEC filing that the Department of Justice subpoenaed the company this month, demanding documents that relate to its manufacturing site in Branchburg, New Jersey, which manufactures its widely-deployed COVID-19 antibody treatment. read more By Amirah Al Idrus Novartis’ foray in COVID-19 therapeutics hit a snag in December, when its Mesoblast-partnered cell therapy failed to help patients with a life-threatening lung injury from COVID-19. But its second effort is gathering steam. The Big Pharma, along with Molecular Partners, is kicking off a phase 2/3 study of its prospect to see whether it can ward off severe disease and hospitalization. read more By Angus Liu Researchers in Taiwan have developed a DNA COVID-19 vaccine that’s delivered into cells with some extra help from electrical pulse. The candidate induced high levels of antibody response in animals and protected hamsters against the disease. read more By Beth Snyder Bulik A year ago, pharma sales reps worried the pandemic would trigger pay cuts. But all may be well that ends well—MedReps' 2021 salary and satisfaction survey found healthy boosts in both income and satisfaction for pharma reps. Average salary increased $8,000 last year to top more than $158,000, while a whopping 85% reported job satisfaction. read more By Kevin Dunleavy,Kevin Dunleavy,Fraiser Kansteiner U.S. intelligence has two theories on the source of COVID-19 but none of the country's three agencies have enough evidence to support any conclusions. Sanofi and GlaxoSmithKline have launched a phase 3 trial of their COVID-19 vaccine candidate and will be ready to manufacture it within weeks. read more By Dave Muoio An unprecedented surge of acute behavioral health presentations during the last three to four months has the pediatric health system and its community partners pleading for increased state and federal resources. read more |
